Abstract| Volume 24, SUPPLEMENT 1, S10, June 2021

# IN3 Economic VALUE and Health System IMPACT of Remdesivir in Treating Hospitalized COVID-19 Patients in the United States

Open Archive

## Objectives

In the ACTT-1 study in hospitalized adults with laboratory confirmed COVID-19, remdesivir was found to be superior to placebo in shortening time to recovery from COVID-19. However, the economic value and health system impact of remdesivir treatment is still unclear. This study evaluated remdesivir’s long-term cost-effectiveness and impact on health system capacities versus standard of care (SoC) for hospitalized COVID-19 patients in the United States (US).

## Conclusions

Remdesivir is a cost-effective option for the treatment of patients hospitalized with mild, moderate, and severe COVID-19 versus SoC. In addition, due to its demonstrated ability to shorten time to recovery, remdesivir is projected to increase treatment capacity by increasing the percentage of available hospital bed-, ICU bed-, and total ventilator capacity.